News
The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback